How do you pay?

How to pay the least

Ask for the cash price

Rasuvo

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you.

  1. Ask your pharmacy for Rasuvo’s cash price, and one or two other pharmacies too.
  2. Rasuvo’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameRasuvo
Authorized genericmethotrexate
Regular genericmethotrexate
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Other forms onlyAsk your doctor
Same as Rasuvo?
The original
–
–

Brand nameThe maker’s card

Rasuvo Co-Pay Assistance Program (CORE Connections)

Savings card from Medexus Pharma

No insuranceNeeds insuranceNo cash price listed.
Insurance · up to $125 off a month

Sign up on rasuvo.com 

Or call 1-855-336-3322.

In the maker’s words

“With the co-pay card you could save up to $125 per month for up to 14 months.”

From the maker’s offer on rasuvo.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Rasuvo itself, from the same company, sold without the brand name, and usually for less. For now Rasuvo is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

Rasuvo is a folate analog metabolic inhibitor indicated for the:

  • Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy
  • Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy

Limitation of Use

Rasuvo is not indicated for the treatment of neoplastic diseases.

Source: the FDA label for Rasuvo (Medexus Pharma Inc.), December 15, 2025. Full label on DailyMed 

Good to know